The incidence of gastric cancer is common. There are approximately 400,000 people getting the disease in China every year. The death number is about 300,000 died. the Chemotherapy is a good way for curing advanced gastric cancer. Most patients’ health situations develop after a chemotherapy treatment. Thus, exploring the safe and effective treatment of gastric cancer is meaningful in advanced stages. The irinotecan has a good effect advanced gastric cancer.

CBR is an indicator for measuring the refractory tumors. It includes the KPS score, and weight gain, including three indicators, new refractory, including gastrointestinal tumors, including tumors, in order to estimate the volume of the indicators of two members all three stable stationary stabilization may be that patients are not valid. In the treatment of gastric cancer is radical, the preferred method, but consider the diagnosis at an advanced stage of about 40% of patients receiving systemic chemotherapy for advanced cancer treatment stomach ulcer is best care support is completed. However, advanced stomach cancer, the American standard therapy programs. Clinical research shows that the line chemotherapy has greater benefit for patient’s survive.

Irinotecan is a topoisomerase I inhibitor Camptothecin derivatives. Topoisomerase I complex formation and replication irinotecan woman topoisomerase I in women's health is a key enzyme, the irreversible destruction of buildings by Ms wife breaks, topoisomerase I is tightly bound with anti-tumor effect. Irinotecan monotherapy for the treatment of stomach cancer is Cornell 18-23% in first line chemotherapy of advanced gastric cancer to determine the status of irinotecan. DDP the first line of treatment is the primary treatment with irinotecan and irinotecan Iraq is divided using DDE with advanced gastric cancer with advanced gastric Cancer LV/5-FU, the overall efficiency is 24%.

In particular, hair loss, diarrhea, acute to Neutropenia cholinergic syndrome, late side effect of irinotecan in the river. Drain flow control module 24 hours, 24% of the rate of incidence of the delay that occurs after administration. Parmaceutical raw materials suppliers inform the patient has chemotherapy in non-diarrhea loperamide preliminary be prefixed to control the symptoms of diarrhea, neutropenia, dose-limiting toxicity of irinotecan in the treatment of the river, 3/4 neutropenia 32% years if necessary, help the chemotherapy G-CSF should be the blood while here. Active cholinergic inhibition of acetylcholinesterase and irinotecan card due to acute cholinergic syndrome neutrophils returned to normal, showing the degree of neutropenia Ⅳ supports the performance of diarrhea beginning early. Tremors, salivation, vomiting, MIO, you have an incident acute cholinergic syndrome was32%.

Once the acute cholinergic syndrome occurs, the use of atropine with subcutaneous injection can make the symptoms disappeared. For the patients with acute cholinergic syndrome in past, the prophylactic atropine will avoid its occurrence. In short, the second-line irinotecan-based chemotherapy can extend overall survival of advanced gastric cancer patients. It has high disease control rate and it is safe. The adverse reactions can be controlled and it is worth further clinical verification.Source:http://www.cospcn.com